{"id":543878,"date":"2021-05-19T22:38:01","date_gmt":"2021-05-19T22:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543878"},"modified":"2021-05-19T22:38:01","modified_gmt":"2021-05-19T22:38:01","slug":"pulmonary-sarcoidosis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novartis-atyr-pharma-relief-therapeutics-ai-therapeutics-and-many-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pulmonary-sarcoidosis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novartis-atyr-pharma-relief-therapeutics-ai-therapeutics-and-many-others_543878.html","title":{"rendered":"Pulmonary Sarcoidosis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics and Many Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1621307980.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Pulmonary Sarcoidosis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics and Many Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1621307980.jpeg\" alt=\"Pulmonary Sarcoidosis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics and Many Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Pulmonary Sarcoidosis Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Sarcoidosis<\/strong> is a rare disease caused by inflammation. It usually occurs in the lungs and lymph nodes, but it can occur in almost any organ. Sarcoidosis in the lungs is called pulmonary sarcoidosis. It causes small lumps of inflammatory cells in the lungs. These lumps are called granulomas and can affect how the lungs work. The cause of pulmonary sarcoidosis is unknown. Experts think that bacteria, viruses, or chemicals might trigger the disease. It may also be genetic.&nbsp;The following are the most common symptoms of pulmonary sarcoidosis.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;<strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-sarcoidosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Pulmonary Sarcoidosis Pipeline<\/a> Insight, 2021,&rdquo;&nbsp;<\/strong>report provides comprehensive insights about <strong>10+ companies and 10+ pipeline drugs<\/strong> in Pulmonary Sarcoidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Pulmonary Sarcoidosis Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Novartis<\/li>\n<li>aTyr Pharma<\/li>\n<li>Relief Therapeutics<\/li>\n<li>AI Therapeutics<\/li>\n<li>SarcoMed USA<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-sarcoidosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/pulmonary-sarcoidosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Pulmonary Sarcoidosis report covers around 10+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III and<\/li>\n<li>Mid-stage products (Phase II and<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-sarcoidosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Pulmonary Sarcoidosis Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>CMK389<\/li>\n<li>ATYR1923<\/li>\n<li>RLF-100<\/li>\n<li>LAM&ndash;001<\/li>\n<li>SM001<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-sarcoidosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/pulmonary-sarcoidosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Pulmonary Sarcoidosis Treatment Scenario and Pulmonary Sarcoidosis Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Pulmonary Sarcoidosis drugs?<\/li>\n<li>How many Pulmonary Sarcoidosis drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for Pulmonary Sarcoidosis?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Sarcoidosis therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Pulmonary Sarcoidosis and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-sarcoidosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/pulmonary-sarcoidosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Pulmonary Sarcoidosis: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Pulmonary Sarcoidosis&ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Pulmonary Sarcoidosis Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">CMK389: Novartis<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I\/II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">ATYR1923: aTyr Pharma<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">LAM&ndash;001: AI Therapeutics<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Pulmonary Sarcoidosis Key Companies<\/p>\n<p style=\"text-align: justify;\">Pulmonary Sarcoidosis Key Products<\/p>\n<p style=\"text-align: justify;\">Pulmonary Sarcoidosis- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Pulmonary Sarcoidosis- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Pulmonary Sarcoidosis- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Pulmonary Sarcoidosis Analyst Views<\/p>\n<p style=\"text-align: justify;\">Pulmonary Sarcoidosis Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/pulmonary-sarcoidosis-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pulmonary-sarcoidosis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novartis-atyr-pharma-relief-therapeutics-ai-therapeutics-and-many-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-sarcoidosis-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/pulmonary-sarcoidosis-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-sarcoidosis-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pulmonary-sarcoidosis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novartis-atyr-pharma-relief-therapeutics-ai-therapeutics-and-many-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pulmonary Sarcoidosis Pipeline Sarcoidosis is a rare disease caused by inflammation. It usually occurs in the lungs and lymph nodes, but it can occur in almost any organ. Sarcoidosis in the lungs is called pulmonary sarcoidosis. It causes small lumps &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pulmonary-sarcoidosis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novartis-atyr-pharma-relief-therapeutics-ai-therapeutics-and-many-others_543878.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-543878","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543878"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543878\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}